These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35002318)

  • 21. Lymphovascular invasion in hormone-positive, human epidermal growth factor-negative, low-burden axillary disease in early breast cancer patients tested for oncotype DX recurrence score.
    Al-Zawi ASA; Yin SL; Aladili Z
    Contemp Oncol (Pozn); 2022; 26(2):139-143. PubMed ID: 35903213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
    Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
    Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX
    Aktas B; Bankfalvi A; Heubner M; Kimmig R; Kasimir-Bauer S
    Mol Clin Oncol; 2013 Nov; 1(6):1049-1054. PubMed ID: 24649291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?
    Auerbach J; Kim M; Fineberg S
    Arch Pathol Lab Med; 2010 Nov; 134(11):1697-701. PubMed ID: 21043825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Estrogen receptors, Progesterone receptors and HER2-neu immunohistochemistry results in breast cancer with those of Oncotype Dx.
    Sughayer MA; Alhassoon S; Sughayer HM
    Ann Diagn Pathol; 2020 Aug; 47():151556. PubMed ID: 32592992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review.
    Glasgow A; Sechrist H; Bomeisl P; Gilmore H; Harbhajanka A
    Breast Cancer; 2021 Mar; 28(2):321-328. PubMed ID: 32951186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.
    Zhang L; Hsieh MC; Petkov V; Yu Q; Chiu YW; Wu XC
    Breast Cancer Res Treat; 2020 Apr; 180(2):491-501. PubMed ID: 32060781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation oncotype DX
    Lashen A; Toss MS; Fadhil W; Oni G; Madhusudan S; Rakha E
    Histopathology; 2023 Apr; 82(5):755-766. PubMed ID: 36631400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A preliminary report of head-to-head comparison of 18-gene-based clinical-genomic model and oncotype DX 21-gene assay for predicting recurrence of early-stage breast cancer.
    Yang PS; Lee YH; Chung CF; Chang YC; Wang MY; Lo C; Tsai LW; Shih KH; Lei J; Yu BL; Cheng SH; Huang CS
    Jpn J Clin Oncol; 2019 Dec; 49(11):1029-1036. PubMed ID: 31287883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of Oncotype DX Recurrence Score Using Clinicopathological Variables in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
    Kim MC; Kwon SY; Choi JE; Kang SH; Bae YK
    J Breast Cancer; 2023 Apr; 26(2):105-116. PubMed ID: 37095618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.
    Roberts MC; Miller DP; Shak S; Petkov VI
    Breast Cancer Res Treat; 2017 Jun; 163(2):303-310. PubMed ID: 28243896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Significance of Oncotype DX 21-Gene Test and Expression of Long Non-Coding RNA MALAT1 in Early and Estrogen Receptor-Positive Breast Cancer Patients.
    Huang Z; Qin Q; Xia L; Lian B; Tan Q; Yu Y; Mo Q
    Cancer Manag Res; 2021; 13():587-593. PubMed ID: 33519238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Convolutional Neural Network Using a Breast MRI Tumor Dataset Can Predict Oncotype Dx Recurrence Score.
    Ha R; Chang P; Mutasa S; Karcich J; Goodman S; Blum E; Kalinsky K; Liu MZ; Jambawalikar S
    J Magn Reson Imaging; 2019 Feb; 49(2):518-524. PubMed ID: 30129697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncotype DX Risk Recurrence Score and Total Mortality for Early-Stage Breast Cancer by Race/Ethnicity.
    Moore J; Wang F; Pal T; Reid S; Cai H; Bailey CE; Zheng W; Lipworth L; Shu XO
    Cancer Epidemiol Biomarkers Prev; 2022 Apr; 31(4):821-830. PubMed ID: 35064066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiological predictive factors on preoperative multimodality imaging are related to Oncotype DX recurrence score in estrogen-positive/human epidermal growth factor receptor 2-negative invasive breast cancer: a cross-sectional study.
    Tsukada H; Tsukada J; Ochi T; Noguchi E; Okamoto T
    Ann Nucl Med; 2022 Oct; 36(10):853-864. PubMed ID: 35819628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia.
    Collin LJ; Yan M; Jiang R; Ward KC; Crawford B; Torres MA; Gogineni K; Subhedar PD; Puvanesarajah S; Gaudet MM; McCullough LE
    NPJ Breast Cancer; 2019; 5():32. PubMed ID: 31583272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The American Joint Commission Cancer 8th Edition Prognostic Stage Including Oncotype DX® Recurrence Score: Impact on Staging of Early Breast Cancer.
    O'Cearbhaill R; Gannon JM; Prichard RS; Walshe JM; McDermott E; Quinn CM
    Pathobiology; 2019; 86(2-3):77-82. PubMed ID: 30347405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).
    Pestalozzi BC; Tausch C; Dedes KJ; Rochlitz C; Zimmermann S; von Moos R; Winterhalder R; Ruhstaller T; Mueller A; Buser K; Borner M; Novak U; Nussbaum CU; Seifert B; Bigler M; Bize V; Vilei SB; Rageth C; Aebi S;
    BMC Cancer; 2017 Apr; 17(1):265. PubMed ID: 28407750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship of Oncotype Dx score with tumor grade, size, nodal status, proliferative marker Ki67 and Nottingham Prognostic Index in early breast cancer tumors in Saudi Population.
    Durrani S; Al-Mushawa F; Heena H; Wani T; Al-Qahtani A
    Ann Diagn Pathol; 2021 Apr; 51():151674. PubMed ID: 33360027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.